Tofacitinib citrate delivery through pharmaceutical formulations for divergent therapeutic treatments
Main Article Content
Abstract
The aim of article is to provide prompt and brief information on all available types of formulations of Tofacitinib citrate. Tofacitinib in the form of Tofacitinib citrate belongs to a new class of therapies called Janus kinase (JAK) inhibitors. Tofacitinib citrate is a medication used to treat rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. Tofacitinib is available in the form of a tablet, an extended-release tablet and as an oral solution. Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even replacing conventional and biological drugs. This article elaborates on the information related to patents of Tofacitinib citrate for its formulation. A survey data for the marketed formulations of Tofacitinib citrate is tabulated. Based on this it is estimated that very less type of formulations pertaining to conventional formulations as tablet or gel is only available in the market. Hence, there is an immediate demand for different type of tofacitinib formulations needed for treatment of extensive cases of arthritis or vitiligo. An extensive literature survey is done on pharmaceutical formulations of Tofacitinib citrate. Based on obtained data it was found these researched and developed formulations can be focused and further initiations can be done to make these formulations marketable. Wholesome, this article assists the reader to quickly grab information on marketed formulations and researched formulations of Tofacitinib citrate.
Downloads
Article Details
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.